AUS
NZ
UK
CA
USA
IND
Highlights
- Defence Therapeutics bolsters its patent portfolio with key US patent allowances and issuances.
- New patents cover Accum®-based dimers, multimers, and vaccine-enhancing variants.
- Strengthened intellectual property paves the way for licensing and strategic partnerships.
Defence Therapeutics Inc. (CSE:DTC) is excited to announce significant advancements in the expansion of its patent portfolio. The company, which is focused on developing cutting-edge radiopharmaceuticals, antibody-drug conjugates (ADCs), and immune-oncology vaccines, has secured several important patent issuances and allowances across multiple jurisdictions. These patents strengthen Defence's intellectual property and pave the way for its ongoing clinical programs, business strategy, and future strategic partnerships.
In May 2023, Defence made a pivotal discovery that multimers based on its proprietary Accum® platform could demonstrate synergistic efficacy and enhanced stability compared to monomeric counterparts. To protect this breakthrough, Defence filed US patent application no. 18/318,384 (the '384 application) and requested a fast-track examination by the United States Patent and Trademark Office (USPTO). On October 17, 2024, the USPTO issued a Notice of Allowance for the application, with the US patent expected to be granted in early 2025 upon payment of the required governmental fees.
The allowed patent application covers valuable composition-of-matter claims related to Accum®-based dimers and multimers. These molecular entities are integral to Defence's AccuTOX® and ARM® anti-cancer programs, both of which are advancing toward clinical development. The claims also extend to these dimers and multimers when conjugated to antigens, carriers, or antibodies—important elements in the development of novel ADCs. The granting of this patent is expected to provide Defence with a long period of market exclusivity in the largest global commercial market for innovative anti-cancer therapeutics, with a patent expiry date projected in 2043. Furthermore, the USPTO's allowance of the '384 application serves as validation of the innovative nature and patentability of Defence's technology, which enhances the company's ability to pursue international filings for the technology in the near future, including the PCT application no. PCT/CA2023/051758.
In addition to the Accum®-based dimer and multimer patent, Defence is also reinforcing its patent portfolio covering its platform vaccine technology. This technology involves covalent conjugation of Accum® and its variants to enhance the immunogenicity of vaccines. Defence has already secured patents for this technology in the United States, Canada, Australia, and Japan. On November 26, 2024, the company added a significant patent to its portfolio with the issuance of US patent no. 12,150,989 (the '989 patent). This patent expands Defence's protection to include Accum®-based immunogenicity-enhancing variants using any steroid acid. This further strengthens the company's position as a leader in developing innovative technologies to improve the potency of vaccines.
Additionally, Defence is pleased to announce that its Singaporean patent application no. 11202304388T has been allowed by the Singaporean Patent Office. The corresponding Singaporean patent is expected to be granted in early 2025 once the requisite governmental fees are paid. These developments underscore Defence's commitment to enhancing its intellectual property portfolio and accelerating the path to strategic licensing and partnerships. With these patents in place, the company is well-positioned to explore opportunities that will further improve the efficacy of vaccines, whether those already approved or still in development.
With a strengthened patent portfolio, Defence Therapeutics is poised to continue its leadership in the development of innovative therapies for cancer treatment and immune-oncology vaccines. These patent allowances and issuances provide the company with a solid foundation for future growth, including the potential for strategic collaborations aimed at bringing these groundbreaking technologies to market.
